Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-318944


Background: The COVID-19 pandemic represented a challenge for intensive care units (ICU) with overwhelming demand, heterogenous outcomes and clinical practices. To improve care a profound knowledge on severe COVID-19 patients during different time points is crucial. This data is still scarce. We aimed to analyze and compare COVID-19 patient demographics, clinical management, and outcomes between two periods from the first pandemic wave.MethodsWe performed a multicentric ambispective cohort study including severe COVID-19 patients between March and August 2020 from 16 Portuguese ICUs. A peak and a plateau period were defined, corresponding to weeks 10-16 and 17-34 of the first pandemic wave. All patients had SARS-CoV-2 pneumonia diagnosis and complete hospital follow-up.ResultsWe included 541 adult patients with a median age of 65 [57-74] years and mostly male (71.2%). Severe acute respiratory distress syndrome developed in 63.9% of cases. Overall, 28-day mortality rate was 23.7% with age and SAPSII (both p<0.001) as independent risk factors.Between peak and plateau periods there were no significant differences in age (65 vs. 66, p=0.6), SAPS II (40 vs. 39, p=0.8), PaO2/FiO2 ratio (139 vs. 136, p=0.6), and antibiotic therapy (57.2% vs. 63.8%, p=0.2) at admission, nor in 28-day mortality (24.4% vs. 22.8%, p=0.7). Adjuvant therapy with corticosteroids had no impact on 28-day mortality (26.9% vs. 22.5% without, p=0.4). The peak period included 53.8% of patients and they had less comorbidities (no comorbidities 29% vs. 36%, p=0.01), presented at admission a higher use of vasopressors (81% vs. 63%, p<0.001), invasive mechanical ventilation (58 vs 49%, p<0.001), prone positioning (60% vs 48%, p=0.009), and hydroxychloroquine (80.2% vs. 13.4%;p<0.001) and lopinavir/ritonavir (60.4% vs. 13.4%;p<0.001) prescription, as compared with the plateau period. In the plateau period, there was a greater use of high flow nasal canula (5% vs 16%, p<0.001) on admission, remdesivir (0.5% vs. 19.9%;p<0.001) and corticosteroid (39% vs. 61%, p<0.001) therapy, and a shorter ICU length-of-stay for survivors (12 days vs. 7, p<0.001).ConclusionThere were significant changes in patient comorbidities, therapies and ICU length-of-stay between peak and plateau periods of the first COVID-19 wave with similar 28-day mortality.

Clin Appl Thromb Hemost ; 28: 10760296221079612, 2022.
Article in English | MEDLINE | ID: covidwho-1685921


BACKGROUND: COVID-19 is a new form of acute respiratory failure leading to multiorgan failure and ICU admission. Gathered evidence suggests that a 3-fold rise in D-dimer concentrations may be linked to poor prognosis and higher mortality. PURPOSE: To describe D-dimer admission profile in severe ICU COVID19 patients and its predictive role in outcomes and mortality. METHODS: Single-center retrospective cohort study. All adult patients admitted to ICU with COVID19 were divided into 3 groups: (1) Lower-values group (D-dimer levels < 3-fold normal range value [NRV] [500ng/mL]), Intermediate-values group (D-dimer ≥3-fold and <10-fold NRV) and Higher-value group (≥10-fold NRV). RESULTS: 118 patients (mean age 63 years, 73% males) were included (N = 73 Lower-values group, N = 31 Intermediate-values group; N = 11 Higher-values group). Mortality was not different between groups (p = 0.51). Kaplan-Meier survival curves revealed no differences (p = 0.52) between groups, nor it was verified even when gender, age, ICU length of stay, and SOFA score were considered as covariables. CONCLUSIONS: In severe COVID19 patients, the D-dimer profile does not retain a predictive value regarding patients' survivability and should not be used as a surrogate of disease severity.

COVID-19/blood , Fibrin Fibrinogen Degradation Products/metabolism , Cohort Studies , Female , Humans , Male , Middle Aged , Prospective Studies , Retrospective Studies , SARS-CoV-2 , Treatment Outcome